Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Mol Cancer Res. 2019 Feb 26;17(6):1351–1364. doi: 10.1158/1541-7786.MCR-18-1068

Figure 6: Arginine metabolites are decreased with combined CPS1 knockdown and EGFR inhibition.

Figure 6:

A. Arginine metabolite levels in HCC4006 cells treated with 100 nM erlotinib for 22 hours B. HCC4006 expressing shNT control or shASL1 treated with vehicle (DMSO) or increasing dose of erlotinib (50 nM and 100 nM) in triplicate for 3 days, followed by 3 days without drug. Cell viability was determined by flow cytometry. C. PC9 expressing shNT control or shASL1 were treated with vehicle (DMSO) or increasing dose of erlotinib (50 nM and 100 nM) in triplicate for 3 days, followed by 3 days without drug. Cell viability was determined by flow cytometry. (ANOVA; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).